Clinical Trials
Is TROP2 Just Not What We Thought It Was for Bladder Cancer? Where to Go after TROPiCS-04?
Sacituzumab govitecan is an antibody drug conjugate that targets TROP-2, a cell-surface glycoprotein highly expressed by bladder cancers. The payload on Sacituzumab govitecan is SN-38, the active metabolite of irinotecan. Sacituzumab govitecan offers a progression-free (PFS) and overall survival (OS) benefit in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies for metastatic disease.1 Subsequently, the TROPiCS-02 trial showed both PFS and OS benefit in patients with confirmed hormone receptor positive and HER2 negative locally-recurrent, inoperable, or metastatic breast cancer.2 These patients had received at least one previous endocrine therapy, a taxane, and a CDK4/6 inhibitor as well as 2 to 4 previous chemotherapy regimens for metastatic disease.
Evan Y. Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.
Clinical Expertise
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
- Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
- Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.